RedCloud Bio has built an innovative pipeline targeting tumor resistance, rare disease and other severe diseases with high unmet medical needs. The Company’s lead therapeutic candidate, H002, a small molecule compound addressing EGFR activating and drug-resistant mutations, is expected to enter clinical trials shortly. H002 is a promising candidate as a fourth generation TKI for NSCLC harboring EGFR activating/drug-resistant mutations.
Our Pipeline
________
Program
 Phase-III
  Phase-II    
   Phase-I   
  IND
Pre-clinical
  Target
 Indication
Click for more information
H002
RC-02      Undisclosed     Undisclosed   
RC-06      Solid Tumor     Undisclosed 
RC-08      Solid Tumor     Undisclosed 
RC-09      Undisclosed     Undisclosed 
RC-11      Undisclosed     Undisclosed 
NSCLC
EGFR
Contact Us

 

Nanjing   ｜307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District Shanghai｜Suite 901, 880 Xiangyang Road, Minhang District Beijing   ｜Suite 205, Building No.2, PKUCare Industrial Park, Changping District Website: https://www.redcloudbio.com

Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved